In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine.
about
DNA vaccination protects mice against Zika virus-induced damage to the testesZika Virus: Recent Advances towards the Development of Vaccines and Therapeutics.Vaccines for Emerging Infectious Diseases: lessons from MERS coronavirus and Zika virus.Impact of prior flavivirus immunity on Zika virus infection in rhesus macaques.Current views on Zika virus vaccine development.Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials.Zika Virus Vaccine Development.Zika vaccine candidates progress through nonclinical development and enter clinical trials.Niclosamide rescues microcephaly in a humanized in vivo model of Zika infection using human induced neural stem cells.Development of Zika Virus Vaccines.Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic.Pregnancy and infection: using disease pathogenesis to inform vaccine strategy.The immunology of Zika Virus.Recombinant Zika virus envelope protein elicited protective immunity against Zika virus in immunocompetent mice.Current status of Zika vaccine development: Zika vaccines advance into clinical evaluation.Developing Zika vaccines: the lessons for disease X.A VSV-based Zika virus vaccine protects mice from lethal challengeIncorporation of NS1 and prM/M are important to confer effective protection of adenovirus-vectored Zika virus vaccine carrying E proteinEvolution of Two Major Zika Virus Lineages: Implications for Pathology, Immune Response, and Vaccine DevelopmentAdenoviral vector type 26 encoding Zika virus (ZIKV) M-Env antigen induces humoral and cellular immune responses and protects mice and nonhuman primates against ZIKV challengeA Nanostructured Lipid Carrier for Delivery of a Replicating Viral RNA Provides Single, Low-Dose Protection against ZikaNew Vaccine Technologies to Combat Outbreak SituationsPurified Inactivated Zika Vaccine Candidates Afford Protection against Lethal Challenge in MiceZika Virus Vaccines: Challenges and Perspectives
P2860
Q30855414-BCE8DE0A-C405-4FD2-BF84-774B8598A986Q32183208-7F20AA8D-8B9C-434E-8896-00A7A13EB3DFQ38156536-582692EF-DD03-43D9-8DA8-BD7871AED690Q38157106-70B8A7A1-1F0B-4298-A1A3-3CB12EE27DF5Q38158576-81582FAE-74D7-43DF-A63C-C9B1E8BFD7B8Q45323630-040DFC10-DB92-4B8C-84AF-2C9DD7372169Q47006432-1EAFF5BF-A32C-4A85-BC2E-8F17A86D4BC8Q47168453-09818E5F-3069-4FDE-B1F4-911BAA3DBCEAQ47548181-E10F2BE3-BCB5-4498-A05B-1CA0CC421820Q47551875-7A8F12BE-B809-4B56-8DF0-D77429110C33Q47570091-D9C2EC60-503E-4A24-BCB7-8620406D2AF8Q48504993-8D3342AA-07EB-4360-A353-E85B3E43C569Q51336389-B8EC1E35-DC5C-4B1D-946B-8B17D4D43B74Q51782806-0A23DA99-5211-4A34-99FB-00C37BDF296BQ55024075-A9C97FAF-7D0D-492D-BE24-28BE1CD1334DQ55426158-A107CB40-3042-4667-9811-EA359DC92120Q56000955-D93CCA52-B6EF-4D71-B814-0FC3F02576B7Q56000963-9232728C-1DB1-4DB8-8555-70AE1A93A5BEQ56000988-90667FC8-159D-403D-AD6F-3D0EF103BAEDQ56337689-CED0F751-72A9-48E7-9AF1-F77A7C91A5D1Q56341976-5A39FDB6-721A-448C-92CB-7C671235CEC2Q57072744-B7EF3703-7098-4FEA-8317-B7D9DF05CE83Q58602667-90FB4BC5-E69E-4CA5-A262-1770E8C2F0D6Q58742686-0341EA02-B9A7-4D99-9761-36CD130D9FF6
P2860
In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine.
description
2016 nî lūn-bûn
@nan
2016 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
In vivo protection against ZIK ...... ion with a prMEnv DNA vaccine.
@ast
In vivo protection against ZIK ...... ion with a prMEnv DNA vaccine.
@en
In vivo protection against ZIK ...... ion with a prMEnv DNA vaccine.
@nl
type
label
In vivo protection against ZIK ...... ion with a prMEnv DNA vaccine.
@ast
In vivo protection against ZIK ...... ion with a prMEnv DNA vaccine.
@en
In vivo protection against ZIK ...... ion with a prMEnv DNA vaccine.
@nl
altLabel
protection against ZIKV infect ...... tion with a prMEnv DNA vaccine
@en
prefLabel
In vivo protection against ZIK ...... ion with a prMEnv DNA vaccine.
@ast
In vivo protection against ZIK ...... ion with a prMEnv DNA vaccine.
@en
In vivo protection against ZIK ...... ion with a prMEnv DNA vaccine.
@nl
P2093
P2860
P50
P921
P1433
P1476
In vivo protection against ZIK ...... ion with a prMEnv DNA vaccine.
@en
P2093
Amelia Anne Keaton
Amir S Khan
Charles C Reed
Christopher Chung
David B Weiner
Elizabeth K Duperret
Emma L Reuschel
Hyeree Choi
J Joseph Kim
P2860
P2888
P356
10.1038/NPJVACCINES.2016.21
P577
2016-11-10T00:00:00Z
P6179
1024329817